DOCSLIB.ORG

Application to Include Fomepizole on the WHO Model List of Essential Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application to Include Fomepizole on the WHO Model List of Essential Medicines Application to Include Fomepizole on the WHO Model List of Essential Medicines Guangduo Zhang, Kasumi Crews, Heather Wiseman, Nicola Bates Medical Toxicology Information Services Ltd., London, UK Knut Erik Hovda The National NBC Center, Department of Acute Medicine, Oslo University Hospital Ullevaal, Oslo, Norway John RH Archer, Paul I Dargan Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK November 2012 Contact Details Heather Wiseman Medical Toxicology and Information Services Ltd. 13 St Thomas' Street, London, UK SE1 9RY [email protected] Knut Erik Hovda The National NBC Centre, Department of Acute Medicine, Oslo University Hospital Ullevaal, Oslo, Norway P.O. Box 4950 Nydalen, NO-0424 Oslo, Norway [email protected] Paul I Dargan Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners Clinical Toxicology, South Wing, 3rd floor, Block C St Thomas' Hospital, Westminster Bridge Road, London, UK SE1 7EH [email protected] Application to Include Fomepizole on the WHO Model List of Essential Medicines 2/85 Contents 1. Summary Statement of the Proposal for Inclusion, Change or Deletion .................................................. 6 2. Name of the Focal Point in WHO Submitting or Supporting the Application ........................................... 7 3. Name of the Organisation(s) Consulted and/or Supporting the Application ............................................ 7 4. International Nonproprietary Name (INN, Generic Name) of the Medicine ............................................ 7 5. Formulation Proposed for Inclusion .......................................................................................................... 7 6. International Availability ........................................................................................................................... 8 7. Whether Listing is requested as an Individual Medicine or as an Example of a Therapeutic Group ........ 8 8. Information Supporting the Public Health Relevance ............................................................................... 8 8.1 Epidemiological Information on Disease Burden of Toxic Alcohol and Glycol Poisoning ................... 8 8.1.1 Toxic Alcohols and Glycols ............................................................................................................ 8 8.1.2 Ethylene Glycol ........................................................................................................................... 10 8.1.3 Methanol .................................................................................................................................... 10 8.1.4 Diethylene Glycol ........................................................................................................................ 12 8.1.5 Other Alcohols and Glycols ......................................................................................................... 13 8.1.6 Disease Burden ........................................................................................................................... 13 8.2 Assessment of Current Use ............................................................................................................... 13 8.2.1 Treatment of Ethylene Glycol and Methanol Poisoning in Adults and Children ........................ 13 8.2.2 Other Indications ........................................................................................................................ 15 8.3 Target Population .............................................................................................................................. 15 9. Treatment Details .................................................................................................................................... 15 9.1 Dosage Regimen and Duration .......................................................................................................... 15 9.1.1 Adults .......................................................................................................................................... 15 9.1.2 Children ...................................................................................................................................... 17 9.1.3 Other Toxic Alcohols ................................................................................................................... 17 9.1.4 Validation of the Current Fomepizole Treatment Regimen ....................................................... 17 9.1.5 Treatment Criteria ...................................................................................................................... 19 9.2 Need for Special Diagnostics ............................................................................................................. 19 9.3 Treatment or Monitoring Facilities and Skills .................................................................................... 20 9.3.1 Treatment Monitoring ................................................................................................................ 20 9.3.2 Need for Haemodialysis ............................................................................................................. 20 10. Summary of Comparative Effectiveness in a Variety of Clinical Settings .............................................. 21 10.1 Identification of Clinical Evidence ................................................................................................... 21 Application to Include Fomepizole on the WHO Model List of Essential Medicines 3/85 10.2 Experimental Evidence of Efficacy of Fomepizole ........................................................................... 22 10.2.1 In vitro Studies .......................................................................................................................... 22 10.2.2 Animal Studies .......................................................................................................................... 22 10.3 Clinical Evidence of Efficacy of Fomepizole ..................................................................................... 23 10.3.1 Quality of Evidence ................................................................................................................... 23 10.3.2 Fomepizole Treatment in Ethylene Glycol Poisoning ............................................................... 24 10.3.3 Fomepizole Treatment in Methanol Poisoning ........................................................................ 25 10.4 Ethanol Treatment in Ethylene Glycol and Methanol Poisoning .................................................... 27 10.5 Comparison of Fomepizole versus Ethanol Treatment ................................................................... 28 10.5.1 Comparison of Fomepizole and Ethanol in Ethylene Glycol Poisoning .................................... 28 10.5.2 Comparison of Fomepizole and Ethanol in Methanol Poisoning ............................................. 29 10.5.3 Practical Considerations ........................................................................................................... 30 10.6 Fomepizole Use in Epidemics .......................................................................................................... 31 11. Summary of Comparative Evidence on Safety ...................................................................................... 32 11.1 Estimate of Total Patient Exposure to Date .................................................................................... 32 11.2 Description of Adverse Effects/Reactions ....................................................................................... 32 11.2.1 Central Nervous System (CNS) Effects...................................................................................... 33 11.2.2 Cardiovascular Effects .............................................................................................................. 33 11.2.3 Gastrointestinal and Metabolic Effects .................................................................................... 34 11.2.4 Dermatological Effects ............................................................................................................. 34 11.2.5 Haematological Effects ............................................................................................................. 34 11.2.6 Other Effects ............................................................................................................................. 34 11.3 Identification of Variation in Safety due to Health Systems and Patient Factors ........................... 36 11.3.1 Paediatrics ................................................................................................................................ 36 11.3.2 Pregnancy and Breast Feeding ................................................................................................. 36 11.3.3 Haemodialysis ........................................................................................................................... 36 11.3.4 Other Factors ............................................................................................................................ 36 11.4 Summary of Comparative Safety against Comparators .................................................................. 37 11.4.1 Adverse Effects of Ethanol ......................................................................................................
Load more

Recommended publications
  • Methanol Interim AEGL Document
    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
    [Show full text]
  • Guideline on Antidote Availability for Emergency Departments January 2017
    Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments January 2017 TOXBASE and/or the BNF should be consulted for further advice on doses and indications for antidote administration and, if necessary, the National Poisons Information Service (NPIS) should be telephoned for more patient-specific advice. Contact details for NPIS are available on TOXBASE. Additional drugs that are used in the poisoned patient that are widely available in ED are not listed in the table – in particular it is important to ensure that insulin, benzodiazepines (diazepam and/or lorazepam), glyceryl trinitrate or isosorbide dinitrate and magnesium are immediately available in the ED. The following drugs should be immediately available in the ED or any area where poisoned patients are initially treated. These drugs should be held in a designated storage facility* The stock held should be sufficient to initiate treatment (stocking guidance is in Appendix 1). Drug Indication Acetylcysteine Paracetamol Activated charcoal Many oral poisons Atropine Organophosphorus or carbamate insecticides Bradycardia Calcium chloride Calcium channel blockers Systemic effects of hydrofluoric acid Calcium gluconate Local infiltration for hydrofluoric acid Calcium gluconate gel Hydrofluoric acid Cyanide antidotes Cyanide Dicobalt edetate The choice of antidote depends on the severity of poisoning, certainty of diagnosis and cause Hydroxocobalamin (Cyanokit®) of poisoning/source of cyanide. Sodium nitrite - Dicobalt edetate is the antidote of choice in severe cases when there is a high clinical Sodium thiosulphate suspicion of cyanide poisoning e.g. after cyanide salt exposure. - Hydroxocobalamin (Cyanokit®) should be considered in smoke inhalation victims who have a severe lactic acidosis, are comatose, in cardiac arrest or have significant cardiovascular compromise - Sodium nitrite may be used if dicobalt edetate is not available.
    [Show full text]
  • Methanol: Toxicological Overview
    Methanol Toxicological Overview Key Points Kinetics and metabolism readily absorbed by all routes and distributed in the body water undergoes extensive metabolism, but small quantities are excreted unchanged by the lungs and in the urine Health effects of acute exposure methanol is toxic following ingestion, inhalation or dermal exposure exposure may initially result in CNS depression, followed by an asymptomatic latent period metabolic acidosis and ocular toxicity, which may result in blindness, are subsequent manifestations of toxicity coma and death may occur following substantial exposures long-term effects may include blindness and, following more substantial exposures, permanent damage to the CNS Health effects of chronic exposure long-term inhalation exposure to methanol has resulted in headaches and eye irritation in workers methanol is considered not to be a mutagen or carcinogen in humans methanol is considered not to be a reproductive toxicant in humans PHE publications gateway number: 2014790 Published: August 2015 Compendium of Chemical Hazards: Methanol Summary of Health Effects Methanol may be acutely toxic following inhalation, oral or dermal exposure. Acute methanol toxicity often follows a characteristic series of features; initially central nervous system (CNS) depression and gastrointestinal tract (GI) irritation may be observed. This is typically followed by a latent period of varying duration from 12–24 hours and occasionally up to 48 hours. Subsequently, a severe metabolic acidosis develops with nausea, vomiting and headache. Ocular toxicity ranges from photophobia and misty or blurred vision to markedly reduced visual acuity and complete blindness following high levels of exposure. Ingestion of as little as 4–10 mL of methanol in adults may cause permanent damage.
    [Show full text]
  • RCEM NPIS Antidote Guideline Appx 1
    Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments (January 2017) Appendix 1. Stock levels & storage recommendations Doses and Clinical Advice on the Administration of Antidotes TOXBASE and/or the BNF should be consulted for further advice on doses and indications for antidote administration. If necessary, the National Poisons Information Service (NPIS) should be telephoned for more patient-specific advice. Contact details for NPIS are available on TOXBASE. Stock Levels The recommended minimum stocking levels (rounded up to full “pack-sizes” where necessary) are based on the amount of antidote required to initiate treatment for an adult patient in the ED and to continue treatment for the first 24 hours. Higher stock levels may be required and individual departments should determine the amount of each antidote they stock based on the epidemiology of poisoning presentations to their department. Additional drugs that are used in the poisoned patient that are widely available in ED are not listed in the table – in particular it is important to ensure that insulin, benzodiazepines (diazepam and/or lorazepam), glyceryl trinitrate or isosorbide mononitrate and magnesium are immediately available in the ED. The following drugs should be immediately available in the ED or any area where poisoned patients are initially treated These drugs should be held in a designated storage facility Recommended stock Drug Indication Presentation Special storage conditions
    [Show full text]
  • Fomepizole for Acetaminophen Toxicity
    Clinical Pharmacology & Toxicology Pearl of the Week Fomepizole for Acetaminophen Toxicity Mechanisms There are two ways that fomepizole works to help prevent hepatotoxicity in APAP overdose. The primary mechanism involves inhibition of CYP450 2E1. o When a toxic amount of APAP is ingested, the pathways that convert it into nontoxic metabolites become overwhelmed. o Thus, more APAP gets converted into NAPQI. o Fomepizole inhibits the 2E1 pathway, thus preventing conversion of APAP into NAPQI. The second mechanism of action is the JNK (“junk”) enzyme. o NAPQI-induced mitochondrial dysfunction leads to formation of reactive oxidant species. This oxidant stress leads to activation of c-jun N-terminal kinase, or JNK, enzyme. o This enzyme translocates to the mitochondria, amplifying oxidant stress, and ultimately resulting in the cessation of ATP production. o Additionally, the JNK enzyme can lead to the rupture of the outer mitochondrial membrane, causing release of intermembrane proteins, which can potentially lead to DNA fragmentation o Interestingly, it is thought that both metabolic acidosis, as well as elevated lactate levels, may be the result of alterations in mitochondrial respiratory function o Fomepizole works by preventing the APAP-induced activation of this enzyme. Role in Acetaminophen poisoning management In cases where fomepizole and NAC were administered together, evidence has shown that the combination has contributed to a decrease in both hepatotoxicity and mortality. Most of the evidence has come from case reports and animal models. Currently, fomepizole is recommended for massive APAP ingestions (as in, ingestions over 500- 600 mg/kg or in cases where 4-hour equivalent acetaminophen concentrations over 5000 umol/L).
    [Show full text]
  • METHANOL 6 (CAS Reg
    1 INTERIM 1: 1/2003 2 INTERIM 2: 2/2005 3 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS 4 (AEGLs) 5 METHANOL 6 (CAS Reg. No. 67-56-1) 7 For 8 NAS/COT Subcommittee for AEGLs 9 February 2005 METHANOL Interim 2: 2/2005 10 PREFACE 11 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the 12 National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 13 (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and 14 other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 15 AEGLs represent threshold exposure limits for the general public and are applicable to emergency 16 exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as 17 appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 18 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the 19 recommended exposure levels are applicable to the general population including infants and children, and 20 other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: 21 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 22 is predicted that the general population, including susceptible individuals, could experience notable 23 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling 24 and are transient and reversible upon cessation of exposure.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Evaluation of the Fate and Transport of Methanol in the Environment
    EVALUATION OF THE FATE AND TRANSPORT OF METHANOL IN THE ENVIRONMENT Prepared For: American Methanol Institute 800 Connecticut Avenue, NW, Suite 620 Washington, DC 20006 Prepared By: Malcolm Pirnie, Inc. 180 Grand Avenue, Suite 1000 Oakland, California 94612 JANUARY 1999 3522-002 TABLE OF CONTENTS Page EXECUTIVE SUMMARY .............................................................................................ES-1 1.0 BACKGROUND .................................................................................................... 1 1.1 Purpose and Scope of Report........................................................................ 1 1.2 Introduction and History of Use ................................................................... 1 1.3 Methanol Production..................................................................................... 3 1.4 Chemical and Physical Properties................................................................. 4 1.5 Release Scenarios ......................................................................................... 5 1.6 Fate in the Environment ............................................................................... 7 2.0 PARTITIONING OF METHANOL IN THE ENVIRONMENT........................... 9 2.1 Methanol Partitioning Between Environmental Compartments .................. 9 2.2 Air/Water Partitioning.................................................................................. 9 2.3 Soil/Water Partitioning................................................................................
    [Show full text]
  • A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City
    A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City To understand the complications and management of • Any methanol ingestion of more than 1 mg/kg may be • Ophtholmalogic manifestations can include methanol toxicity. lethal. mydriasis, retinal edema leading to retinal sheen, afferent pupillary defect, and, most commonly, toxic • Methanol itself is relatively non-toxic, causing only CNS optic neuropathy. depression; the more severe manifestations of methanol History of Present Illness toxicity are related to the breakdown product formic acid • Studies have shown the optimal treatment of toxic or formate. optic neuropathy is high dose solumedrol followed • 41 year old female with depression, seizure disorder, by a prednisone taper. alcohol abuse, and history of multiple suicide attempts • Metabolism of methanol: alcohol dehydrogenase oxidizes presented to the emergency department reporting that methanol to form formaldehyde which is then oxidized to • It is important to assess the mental health of she had ingested anti-freeze and alcohol and inhaled formic acid. Formic acid is oxidized to non-toxic carbon patients treated for methanol ingestion to gasoline in an attempt to commit suicide. dioxide and water by folate dependent reactions. determine intent and risk of additional self-harm. Physical Exam • Initial manifestations of methanol overdose can be mild • Successful treatment of methanol ingestion requires • Normal vital signs confusion and the appearance of intoxication. early recognition and aggressive multifactorial • Mild suprapubic tenderness medical management aimed at decreasing the levels • Laboratory testing classically shows significant metabolic • Slurred speech and inappropriate affect but alert and of methanol and its metabolites and preventing acidosis with extremely high anion gap and high osmolar answer questions long-term end organ damage.
    [Show full text]
  • 'Tis the Season for Antifreeze…And Its Toxicities!
    VETTALK Volume 15, Number 02 American College of Veterinary Pharmacists ‘Tis the Season for Antifreeze…and its Toxicities! Introduction outcomes. As with ethanol and methanol, resembles ethanol (alcohol) intoxication. Antifreeze is known to most as the EG is also metabolized by ADH to form Dogs and cats exhibit vomiting due to GI neon green liquid that goes into our cars glycoaldehyde which is then oxidized to irritation, polydipsia, polyuria, and neu- to lower the freezing point and prevent glycolate, glyoxalate, and oxalate. Gly- rologic signs such as CNS depression, our radiators from locking up in cold colate and oxalate are responsible for stupor, ataxia, knuckling, decreased with- weather. However, to veterinarians and metabolic acidosis and renal damage. drawal or righting reflexes. Polydipsia veterinary pharmacists, it is ethylene gly- This is because ethylene glycol metabo- occurs due to osmotic stimulation of the col, a source of tens of thousands of ani- lites target the kidney and lead to oliguric thirst center, and polyuria occurs due to mal poisonings each year, the majority of or anuric acute renal injury, which in turn an osmotic diuresis. As CNS depression which occur in late fall, winter, and early slows elimination of ethylene glycol mak- increases in severity, dogs and cats drink spring which is why the timing appeared ing toxicity worst. The process of renal less, however the osmotic diuresis contin- suitable for this newsletter. The other failure is primarily due to glycolate- ues and results in severe dehydration. reason for publishing this article now is induced direct damage to tubules, al- Dogs may appear to transiently recover that the antidote for antifreeze poisoning, though tubule obstruction from precipi- from these CNS signs approximately 12 Antizol-Vet®(fomepizole), is on indefi- tated oxalate crystals may contribute as hours after ingestion.
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Methanol Toxicity Outbreak: When Fear of COVID-19 Goes Viral
    PostScript LETTER in several other centres throughout the Patient and public involvement Patients and/or Emerg Med J: first published as 10.1136/emermed-2020-209886 on 15 May 2020. Downloaded from country during this period. the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer Unlike prior outbreaks, the current Methanol toxicity outbreak: to the Methods section for further details. outbreak of methanol poisoning appears Patient consent for publication Not required. when fear of COVID-19 to be due to the belief that consumption of disinfectants and sanitizers, specif- Provenance and peer review Not commissioned; goes viral internally peer reviewed. ically, alcohol, would be beneficial in preventing the COVID-19 infection. This This article is made freely available for use in Dear editor accordance with BMJ’s website terms and conditions is supported by several cases of methanol for the duration of the covid-19 pandemic or until Methanol ingestion can be a highly poisoning in children resulting from a otherwise determined by BMJ. You may use, download lethal poisoning; methanol is metabolised desperate attempt by parents to prevent and print the article for any lawful, non- commercial to formaldehyde and formic acid, which or cure the infection. When facing a purpose (including text and data mining) provided that all copyright notices and trade marks are retained. are extremely toxic to the central nervous serious health threat, refractory to the system and the gastrointestinal tract available remedies, such irrational deci- © Author(s) (or their employer(s)) 2020. No commercial re- use.
    [Show full text]